ABIVAX Société Anonyme (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have received an average rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $38.67.

Several research firms have issued reports on ABVX. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the period. Walleye Capital LLC increased its position in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares during the period. abrdn plc lifted its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after acquiring an additional 119,300 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Trading Down 2.2 %

Shares of ABIVAX Société Anonyme stock opened at $6.23 on Thursday. ABIVAX Société Anonyme has a 12-month low of $5.54 and a 12-month high of $17.02. The business’s 50 day moving average is $7.72 and its 200-day moving average is $10.05.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.